The drugs don't sell: DIY heart health and the over-the-counter statin experience

Social Science and Medicine

Volumn 131, Issue , 2015, Pages 280-288

  Will, Catherine M ^a   Weiner, Kate ^b,c,d  

^a UNIVERSITY OF SUSSEX   (United Kingdom)

^b UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^c UNIVERSITY OF MANCHESTER   (United Kingdom)

^d UNIVERSITY OF SHEFFIELD   (United Kingdom)

Author keywords

Choice; Citizen; Consumer; OTC; Patient; Pharmaceutical; UK

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; NON PRESCRIPTION DRUG;

ATTITUDE TO HEALTH; CARDIOVASCULAR DISEASES; DRUG INDUSTRY; DRUG MISUSE; HEALTH BEHAVIOR; LIFESTYLE; MANAGEMENT; MARKETING; PATIENT SATISFACTION; SELF MEDICATION; UNITED KINGDOM;

ATTITUDE TO HEALTH; CARDIOVASCULAR DISEASES; DRUG INDUSTRY; GREAT BRITAIN; HEALTH BEHAVIOR; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LIFE STYLE; MARKETING; NONPRESCRIPTION DRUGS; PATIENT SATISFACTION; POLICY MAKING; PRESCRIPTION DRUG OVERUSE; SELF MEDICATION;

EID: 84939896077     PISSN: 02779536     EISSN: 18735347     Source Type: Journal    
DOI: 10.1016/j.socscimed.2014.04.033     Document Type: Article

References (47)

1. Abraham J. From Evidence to Theory - Neo-liberal corporate bias as a framework for understanding UK pharmaceuticals regulation: response to Alison Edgley. Social Theory and Health 2007, 5(2):161-175.
2. Abraham J. The sociological concomitants of the pharmaceutical industry and medications. Handbook of Medical Sociology 2010, 290-308. Vanderbilt University Press, Nashville. C.E. Bird, P. Conrad, A.M. Fremont, S. Timmermans (Eds.).
3. Abraham J. Pharmaceuticalization of society in context: Theoretical, Empirical and health Dimensions. Sociology 2010, 44(4):603-622.
4. Bauman Z. Work, Consumerism and the New Poor 2005, Open University Press, Maidenhead. second ed.
5. Bell S., Figert A. Medicalization and pharmaceuticalization at the intersections: looking backward, Sideways and forward. Social Science & Medicine 2012, 75(5):775-783.
6. Benner J.S., Glynn R.J., Mogun H., Neumann P.J., Weinstein M.C., Avorn J. Long term persistence in use of statin therapy in elderly patients. Journal of the American Medical Association 2002, 288:455-461.
7. Biehl J. Drugs for all: the future of global AIDS treatment. Medical Anthropology 2008, 27(2):99-105.
8. Calnan M., Williams S. Style of life and the salience of health: an exploratory study of health related practices in households from differing socio-economic circumstances. Sociology of Health & Illness 1991, 13(4):506-529.
9. Clarke A.E. SituAtional Analysis: Grounded Theory after the Postmodern Turn 2005, Sage, Thousand Oaks, CA.
10. Clarke J., Newman J., Smith N., Vidler E., Westmarland L. Creating Citizen-Consumers: Changing Publics and Changing Public Services 2007, Sage, London.
11. National Service Framework for Coronary Heart Disease: Modern Standards and Service Models 2000, Department of Health, Department of Health, London.
12. Choosing Health through Pharmacy. A Programme for Pharmaceutical Public Health 2005, Department of Health.
13. Dumit J. Drugs for Life: How Pharmaceutical Companies Define Our Health 2012, Duke University Press, Durham.
14. Edgely A. Aspoonful of regulation helps the medicine go down': the changing face of medicine regulation. Social Theory and Health 2007, 5(2):145-160.
15. Epstein S. Impure Science: AIDS, Activism, and the Politics of Knowledge 1996, University of California Press, Berkley.
16. Fishman Jennifer R. Manufacturing desire: the commodification of female sexual dysfunction. Social Studies of Science 2004, 34(2):187-218.
17. Fox N.J. Health identities: from expert patient to resisting consumer. Health 2006, 10(4):461-479.
18. Fox N.J., Ward K.J., ÓRourke A.J. The 'expert patient': empowerment or medical dominance? The case of weight loss, pharmaceutical drugs and the internet. Social Science & Medicine 2005, 60(6):1299-1309.
19. Fox N.J., Ward K.J., ÓRourke A.J. The birth of the e-clinic. Continuity or transformation in the UK governance of pharmaceutical consumption?. Social Science & Medicine 2005, 61:1474-1484.
20. Gibbon S. Charity, breast cancer activism and the iconic figure of the BRCA carrier. Biosocialities, Identity and the Social Sciences 2007, Routledge, London. S. Gibbon, C. Novas (Eds.).
21. Greene J. Prescribing by Numbers: Drugs and the Definition of Disease 2007, Johns Hopkins University Press, Baltimore.
22. Hammersley M., Atkinson P. Ethnography: Principles in Practice 1995, Routledge, London.
23. Hansen D.L., Hansen E.H. Caught in a balancing act: parents' dilemmas regarding their ADHD child's treatment with stimulant medication. Qualitative Health Research 2006, 16(9):1267-1285.
24. Henwood F., Wyatts S., Hart A., Smith J. Ignorance is bliss sometimes': constraints on the emergence of the 'informed patient' in the changing landscapes of health information. Sociology of Health & Illness 2003, 25(6):589-607.
25. Lupton D. Consumerism, reflexivity and the medical encounter. Social Science & Medicine 1997, 43(3):373-381.
26. Lupton D., Donaldson C., Lloyd P. Caveat emptor or blissful ignorance? Patients and the consumerist ethos. Social Science & Medicine 1991, 33(5):559-568.
27. Mantel-Teeuwisse A.K., Goettsch W.G., Klungel O.H., de Boer A., Herings R.M. Long term persistence with statin treatment in daily medical practice. Heart 2004, 90:1065-1066.
28. Matthews P. Is 'Knowing Your Number Worth It?' The Independent 1993, London. August 22.
29. McDonald R., Mead N., Cheraghi-Sohi S., Bower P., Whalley D., Roland M. Governing the ethical consumer: identity, choice and the primary care medical encounter. Sociology of Health & Illness 2007, 29(3):430-456.
30. Consultation ARM 18 2003, MHRA, (accessed 27.09.13). http://www.mhra.gov.uk/Publications/Consultations/Medicinesconsultations/ARMs/CON007750.
31. Heart Drug Available without Prescription 2004, MHRA, Press Release, (accessed 27.09.13). http://www.mhra.gov.uk/NewsCentre/Pressreleases/CON002050.
32. Moncrieff J. Response to 'A spoonful of regulation helps the medicine go down'. Social Theory and Health 2007, 5:176-179.
33. Moreira T. When are trials not enough? Clinical versus cost-effectiveness in the controversy over access to dementia drugs in the NHS. Medical Proofs, Social experiments. Clinical Trials in Shifting Contexts 2010, 85-102. Ashgate, Aldershot. Will, Moreira (Eds.).
34. Lipid Modification: Cardiovascular Risk Assessment and the Modification of Blood Lipids for the Primary and Secondary Prevention of Cardiovascular Disease 2008, NICE, National Institute for Health and Clinical Excellence, London.
35. Draft Guidance For Consultation. Lipid Modification: Cardiovascular Risk Assessment and the Modification of Blood Lipids for the Primary and Secondary Prevention of Cardiovascular Disease 2014, NICE, National Institute for Health and Care Excellence, London.
36. Noerreslet M., Jemec G.B.E., Traulsen J.M. Involuntary autonomy: patients' perceptions of physicians, conventional medicines and risks in the management of atopic dermatitis. Social Science & Medicine 2009, 69(9):1409-1415.
37. Global Pharmaceuticals: Ethics, Markets, Practices 2006, Duke University Press, Durham. A. Petryna, A. Lakoff, A. Kleinman (Eds.).
38. Pollan M. Unhappy Meals 2007, The New York Times, New York.
39. Pound P., Britten N., Morgan M., Yardley L., Pope C., Daker-White G., et al. Resisting medicines: a synthesis of qualitative studies of medicine taking. Social Science & Medicine 2005, 61:133-155.
40. Rose N., Novas C. Biological citizenship. Global Assemblages: Technology, Politics and Ethics as Anthropological Problems 2005, Blackwell, London. A. Ong, S. Collier (Eds.).
41. Tinetti M. Over-the-counter sales of statins and other drugs for asymptomatic conditions. New England Journal of Medicine 2008, 358(25):2728-2732.
42. Wanless D. Securing our Future Health: Taking a Long-term View 2002, HM Treasury, London.
43. Wanless D. Securing Good Health for the Whole Population: Final Report 2004, HM Treasury, London.
44. Will C.M. Arguing about the evidence: readers, writers and inscription devices in coronary heart disease risk assessment. Sociology of Health & Illness 2005, 27:780-801.
45. Williams S.J., Martin P., Gabe J. The pharmaceuticalisation of society? A framework for analysis. Sociology of Health & Illness 2011, 33(5):710-725.
46. Williams S., Gabe J., Martin P. Medicalization and pharmaceuticalization at the intersections: a commentary on Bell and Figert. Social Science & Medicine 2012, 75(12):2129-2130.
47. Wyatt S. Non-users also matter: the construction of users and non-users of the internet. How Users Matter: the Co-construction of Users and Technology 2005, 67-79. MIT Press, Cambridge, Mass. N. Oudshoorn, T. Pinch (Eds.).